Современная концепция патофизиологии и новые мишени терапии мигрени
https://doi.org/10.14412/2074-2711-2020-4-143-152
Аннотация
Мигрень является распространенным хроническим неврологическим заболеванием. Патофизиология головной боли и других проявлений мигрени предполагает участие множества нейрогенных, сосудистых, вегетативных и других механизмов, реализующихся на разных уровнях центральной и периферической нервной системы. Достижения в понимании нейробиологии мигрени позволили уточнить основные закономерности функционирования нейрогенно-сосудистых взаимоотношений, объясняющих ведущие клинические проявления мигрени, а также выявить некоторые биологические маркеры, которые послужили толчком к созданию новых классов таргетной терапии заболевания. Данный обзор посвящен последним достижениям в изучении патофизиологии мигрени и новым фармакологическим подходам к ее лечению.
Ключевые слова
мигрень,
патофизиология,
тригеминоваскулярная система,
кальцитонин-ген родственный пептид,
анти-CGRP моноклональные антитела
При поддержке: Статья публикуется при поддержке ООО «Тева». Авторы не получали финансовое вознаграждение за подготовку статьи.
Об авторах
Г. Р. Табеева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
Гюзяль Рафкатовна Табеева
Кафедра нервных болезней и нейрохирургии
2119021, Москва, ул. Россолимо, 11, стр. 1
З. Кацарава
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет); University of Duisburg-Essen, University Hospital; Evangelical Hospital; EVEX Medical Corporation
Россия
2119021, Москва, ул. Россолимо, 11, стр. 1
Россия
2119021, Москва, ул. Россолимо, 11, стр. 1
Список литературы
1. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi: 10.1016/S0140-6736(17)32154-2
2. Lipton RB, Bigal ME, Diamond M, et al; Advisory Group AMPP. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-9. doi: 10.1212/01.wnl.0000252808.97649.21
3. Eadie MJ. A history of migriane. In: Borsook D, May A, Goadsby PJ, Hargeaves R, eds. The Migraine Brain. New York: Oxford University Press; 2012. P. 3-16.
4. Willis T, Pordage S. Two Discourses Concerning the Soul of Brutes, which Is that of the Vital and Sensitive of Man: The First Is Physiological, Shewing the Nature, Parts, Powers, And Affections Of The Same; And The Other Is Pathological, Which Unfolds the Diseases Which Affect It and Its Primary Seat, to Wit, the Brain and Nervous Stock, and Treats of Their Cures: With Copper Cuts. London: Dring, Harper and Leigh; 1683.
5. Liveing E. On Megrim, Sick-Headache, and Some Allied Disorders. A Contribution to the Pathology of Nerve-Storms. London: Arts & Boeve Nijmegen; 1873.
6. Wolff HG. Headache and other head pains, 2 nd ed. New York: Oxford University Press; 1963.
7. Goadsby PJ, Holland PR, MartinsOliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553-622. doi: 10.1152/physrev.00034.2015
8. Marmura MJ. Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep. 2018 Oct 5;22(12):81. doi: 10.1007/s11916-018-0734-0
9. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nature Rev Neurosci. 2011;12:570-84. doi: 10.1038/nrn3057
10. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89-99. doi: 10.3988/jcn.2012.8.2.89
11. Charles A. Migraine: a brain state. Curr Opin Neurol. 2013;26:235-9. doi: 10.1097/WCO.0b013e32836085f4
12. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia. 2007;27:1427-39. doi: 10.1111/j.14682982.2007.01500.x
13. Tolner EA, Houben T, Terwindt GM, et al. From migraine genes to mechanisms. Pain. 2015;156 Suppl 1:S64-74. doi: 10.1097/01.j.pain.0000460346.00213.16
14. Van Oosterhout W, van Someren E, Schoonman GG, et al. Chronotypes and circadian timing in migraine. Cephalalgia. 2017. doi: 10.1177/0333102417698953
15. Burstein R, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-29. doi: 10.1523/JNEUROSCI.0373-15.2015
16. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137:232-41. doi: 10.1093/brain/awt320
17. Moulton EA, Becerra L, Johnson A, et al. Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine. PLoS One. 2014 Apr 17;9(4):e95508. doi: 10.1371/journal.pone.0095508
18. Dodick DW. Phase-by-phase review of migraine pathophysiology. Headache. 2018;58:4-16. doi: 10.1111/head.13300
19. Wei X, Yan J, Tillu D, et al. Meningeal norepinephrine produces headache behaviors in rats via actions both on dural afferents and fibroblasts. Cephalalgia. 2015;35:1054-64. doi: 10.1177/0333102414566861
20. Schulte LH, May A. The migraine generator revisited: Continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139:1987-93. doi: 10.1093/brain/aww097
21. Borsook D, Burstein R. The enigma of the dorsolateral pons as a migraine generator. Cephalalgia. 2012;32:803-12. doi: 10.1177/0333102412453952
22. Viana M, Linde M, Sances G, et al. Migraine aura symptoms: duration, succession and temporal relationship to headache. Cephalalgia. 2016;36:413-21. doi: 10.1177/0333102415593089
23. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry. 1941;46:331-9. doi: 10.1001/archneurpsyc.1941.02280200137007
24. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7:359-90. doi: 10.1152/jn.1944.7.6.359
25. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981;9:344-52. doi: 10.1002/ana.410090406
26. Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001;98:4687-92.
27. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365-91. doi: 10.1146/annurev-physiol030212-183717
28. Charles A, Hansen JM. Migraine aura: New ideas about cause, classification, and clinical significance. Curr Opin Neurol. 2015;28:255-60. doi: 10.1097/WCO.0000000000000193
29. Zhang X, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci. 2010 Jun 30;30(26):8807-14. doi: 10.1523/JNEUROSCI.0511-10.2010
30. Lambert GA, Hoskin KL, Zagami AS. Cortico-NRM influences on trigeminal neuronal sensation. Cephalalgia. 2008;28:640-52. doi: 10.1111/j.1468-2982.2008.01572.x
31. Goadsby PJ. Parallel concept of migraine pathogensis. Ann Neurol. 2002;51:140. doi: 10.1002/ana.10025
32. Bartsch T, Goadsby PJ. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Curr. 2005;2:42-8. doi: 10.1111/j.17435013.2005.20201.x
33. Noseda R, Jakubowski M, Kainz V, et al. Cortical projections of functionally identified thalamic trigeminovascular neurons: Implications for migraine headache and its associated symptoms. J Neurosci. 2011;31:14204-17. doi: 10.1523/JNEUROSCI.3285-11.2011
34. Messlinger K, Fischer MJ, Lennerz JK. Neuropeptide effects in the trigeminal system: Pathophysiology and clinical relevance in migraine. Keio J Med. 2011;60:82-9. doi: 10.2302/kjm.60.82
35. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013 Dec;154 Suppl 1:S44-S53. doi: 10.1016/j.pain.2013.07.021
36. Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010;13(2):239-45. doi: 10.1038/nn.2475
37. Magis D, Lisicki M, Coppola G. Highlights in migraine electrophysiology: Are controversies just reflecting disease heterogeneity? Curr Opin Neurol. 2016;29:320-30. doi: 10.1097/WCO.0000000000000335
38. Schwedt TJ, Chiang CC, Chong CD, Dodick DW. Functional MRI of migraine. Lancet Neurol. 2015;14:81-91. doi: 10.1016/S1474-4422(14)70193-0
39. Кондратьева НС, Анучина АА, Кокаева ЗГ и др. Генетика мигрени (обзор). Медицинская генетика. 2016;(1):3-12.
40. Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann Neurol. 1997;41:166-72. doi: 10.1002/ana.410410207
41. Gervil M, Ulrich V, Kaprio J, Russell MB. Is the genetic liability in multifactorial disorders higher in concordant than discordant monozygotic twin pairs? A population-based family twin study of migraine without aura. Eur J Neurol. 2001;8:231-35. doi: 10.1046/j.1468-1331.2001.00188.x
42. Ulrich V, Gervil M, Kyvik KO, et al. Evidence of a genetic factor in migraine with aura: a population based Danish twin study. Ann Neurol. 1999;45:242-6. doi: 10.1002/1531-8249(199902)45:2<242::AIDANA15>3.0.CO;2-1
43. Goadsby PJ. Bench to bedside advances in the 21 st century for primary headache disorders: migraine treatments for migraine patients. Brain. 2016;139(Pt 10):2571-7. doi: 10.1093/brain/aww236
44. Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240-4. doi: 10.1038/298240a0
45. Edvinsson L. The journey to establish CGRP as a migraine target: a retrospective view. Headache. 2015;55:1249-55. doi: 10.1111/head.12656
46. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-50. doi: 10.1038/s41582-0180003-1
47. Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19:3423-9. doi: 10.1523/JNEUROSCI.1909-03423.1999
48. Villalon CM, van den Brink AM. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev Med Chem. 2017;17:928-38. doi: 10.2174/1389557516666160728121050
49. Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1 F receptor agonist lasmiditan in the acute treatment of migraine. Exp Opin Pharmacother. 2017;18:1409-15. doi: 10.1080/14656566.2017.1361406
50. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48-56. doi: 10.1002/ana.410330109
51. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-7. doi: 10.1002/ana.410280213
52. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179-86. doi: 10.1177/0333102410368444
53. Raddant AC, Russo AF. Calcitonin generelated peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011 Nov 29;13:e36. doi: 10.1017/S1462399411002067
54. Maasumi K, Michael RL, Rapoport AM. CGRP and migraine: the role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs. 2018 Jun;78(9):913-28. doi: 10.1007/s40265-0180923-5
55. Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58 Suppl 1:33-47. doi: 10.1111/head.13305
56. Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171-82. doi: 10.1111/head.12642
57. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-38. doi: 10.1038/nrd3003
58. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019 Apr 17;20(1):37. doi: 10.1186/s10194-019-0974-3
59. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2014;34:483-92. doi: 10.1177/0333102413517775
60. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113-22. doi: 10.1056/NEJMoa1709038
61. Dodick DW, Silberstein SD, Bigal ME, et al. Еffect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999-2008. doi: 10.1001/jama.2018.4853
62. Cohen JM, Dodick DW, Yang R, et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017;57:1375-84. doi: 10.1111/head.13156
Рецензия
Для цитирования:
Табеева ГР, Кацарава З. Современная концепция патофизиологии и новые мишени терапии мигрени. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):143-152. https://doi.org/10.14412/2074-2711-2020-4-143-152
For citation:
Tabeeva GR, Katsapava Z. Current concept of the pathophysiology of migraine and new targets for its therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):143-152. https://doi.org/10.14412/2074-2711-2020-4-143-152
Просмотров:
1680
Послать статью по эл. почте 